SULMEPRIM PEDIATRIC Drug Patent Profile
✉ Email this page to a colleague
When do Sulmeprim Pediatric patents expire, and when can generic versions of Sulmeprim Pediatric launch?
Sulmeprim Pediatric is a drug marketed by Usl Pharma and is included in one NDA.
The generic ingredient in SULMEPRIM PEDIATRIC is sulfamethoxazole; trimethoprim. There are twenty-seven drug master file entries for this compound. Forty-nine suppliers are listed for this compound. Additional details are available on the sulfamethoxazole; trimethoprim profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Sulmeprim Pediatric
A generic version of SULMEPRIM PEDIATRIC was approved as sulfamethoxazole; trimethoprim by SUN PHARM INDUSTRIES on August 25th, 1986.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for SULMEPRIM PEDIATRIC?
- What are the global sales for SULMEPRIM PEDIATRIC?
- What is Average Wholesale Price for SULMEPRIM PEDIATRIC?
Summary for SULMEPRIM PEDIATRIC
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Raw Ingredient (Bulk) Api Vendors: | 27 |
Clinical Trials: | 1 |
Patent Applications: | 2,533 |
DailyMed Link: | SULMEPRIM PEDIATRIC at DailyMed |
Recent Clinical Trials for SULMEPRIM PEDIATRIC
Identify potential brand extensions & 505(b)(2) entrants
Sponsor | Phase |
---|---|
Roswell Park Cancer Institute | Phase 4 |
National Cancer Institute (NCI) | Phase 4 |
US Patents and Regulatory Information for SULMEPRIM PEDIATRIC
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Usl Pharma | SULMEPRIM PEDIATRIC | sulfamethoxazole; trimethoprim | SUSPENSION;ORAL | 070064-001 | Aug 1, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |